跳到正文
原文
STAT 主站· Adam Feuerstein·· 30 分钟前AI 评分45

FDA 拒绝 Capricor Therapeutics 的 Duchenne 肌营养不良疗法

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

AI 导读

FDA 拒绝了 Capricor Therapeutics 开发的用于 Duchenne 肌营养不良的细胞疗法 deramiocel。两项随机临床试验均未显示该疗法能延缓心脏衰竭或保持手臂肌肉功能。该疗法未能帮助已失去行走能力的青少年和年轻男性患者。

正文

A public pressure campaign couldn’t alter the hard reality: The drug didn’t work

Sarah Silbiger/Getty Images

By Adam Feuerstein

Nov. 20, 2026

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics. 

The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms. 

But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

来源:STAT 主站 · statnews.com